The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
 
Tara C. Gangadhar
Honoraria - Medscape
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Bryan J. Schneider
Consulting or Advisory Role - Clovis Oncology; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); OncoMed (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Jeffrey S. Wasser
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Johnson & Johnson; Lilly; Merck (I); Pfizer (I)
Consulting or Advisory Role - Amgen; Novartis
Research Funding - Amgen; Incyte; Pfizer
Travel, Accommodations, Expenses - Amgen
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Sandip P. Patel
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Bristol-Myers Squibb; Incyte; Lilly; MedImmune; Pfizer; Roche/Genentech; Xcovery
 
Ani Sarkis Balmanoukian
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Merck
Research Funding - Genentech; Incyte; MedImmune; Merck; Merck Serono
 
Joshua Bauml
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Guardant Health; Merck
Research Funding - Bayer (Inst); Carevive Systems (Inst); Incyte; Merck (Inst); Novartis (Inst)
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Amgen (I); Incyte
Travel, Accommodations, Expenses - Amgen (I); Incyte
 
Mark M. Jones
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst)